Fig. 1 · Structure

Documents & Downloads

Terbinafine hydrochloride

Cat. No. A10912 CAS 78628-80-5
Terbinafine HCl a member of the allylamine class of antifungals, has been found to be a specific inhibitor of ergosterol synthesis via squalene epoxidase inhibition.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
squalene epoxidase

Terbinafine hydrochloride Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Terbinafine hydrochloride from 3 published references. In vitro models include HT29; SNU449 cells.

Terbinafine hydrochloride In Vitro Studies

Terbinafine dose-dependently suppressed cell viability in HT29 cells. In SNU449 cells evaluated with Terbinafine and an untreated control, the reported result was that SQLE inhibition significantly downregulated the indicated oxysterol levels in HCC cells. Terbinafine treatment at 50 µM for 48 h strongly reduced SOAT1 mRNA expression in C4-2 cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Terbinafine suppresses HT29 cell viability

Cell-based study · HT29 [1]

Terbinafine treatment dose-dependently suppressed cell viability in HT29 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result dose-dependently suppressed cell viability[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Terbinafine

The paper names Terbinafine without stating the salt or form; not verified as the hydrochloride form supplied as A10912. No dose conversion or lot validation.

Figure 7 legend (S223)

cell viability: cell viability — Figure 7 legend (S223)

Oxysterol levels in SNU449 cells

Cell-based study · SNU449 cells [2]

Terbinafine was evaluated in SNU449 cells with an untreated control. The reported result was that SQLE inhibition significantly downregulated the indicated oxysterol levels in HCC cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The levels of indicated oxysterolsReported result SQLE inhibition significantly downregulated the levels of all three oxysterols in HCC cells[2]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Terbinafine

The paper names Terbinafine without stating the salt or form; not verified as the hydrochloride form supplied as A10912. No dose conversion or lot validation.

Results > SQLE orchestrates oxysterols production in HCC cells by modulating cholesterol metabolism (S171); Figure 3 legend (S252)

The levels of indicated oxysterols: The levels of indicated oxysterols; comparator: untreated (Med) — Results > SQLE orchestrates oxysterols production in HCC cells by modulating cholesterol metabolism (S171); Figure 3 legend (S252)

Terbinafine reduces SOAT1 mRNA expression

Cell-based study · C4-2 cells [3]

C4-2 cells were treated with Terbinafine at 50 µM for 48 h. Treatment resulted in a strong reduction in SOAT1 mRNA expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Expression of SOAT1 mRNAReported result terbinafine treatment resulted in a strong reduction in SOAT1 mRNA expression[3]

Literature-Reported Treatment Conditions

Treatment concentration
50 µM
Exposure duration
48 h
Reported limits
Not stated in the sentences used: route, vehicle, control.
Methods and source locations

Compound reported in the paper: Terbinafine

The paper names Terbinafine without stating the salt or form; not verified as the hydrochloride form supplied as A10912. No dose conversion or lot validation.

Results > MiR-205 and SQLE regulate cholesterol synthesis in PCa cells (S45); Fig. 3 legend (S352)

Expression of SOAT1 mRNA: Expression of SOAT1 mRNA — Results > MiR-205 and SQLE regulate cholesterol synthesis in PCa cells (S45); Fig. 3 legend (S352)

Terbinafine hydrochloride In Vivo Studies

Terbinafine was administered to male CB17-SCID mice bearing orthotopically implanted VCaP cells at 50 mg/kg by intraperitoneal injection every 48 h. Tumour growth was reduced compared with vehicle controls, with significant differences reported. [3]

Terbinafine reduces tumour growth in an orthotopic prostate model

Animal study · male CB17-SCID mice; VCaP cells are orthotopically implanted into the prostate glands; n = 7 [3]

Male CB17-SCID mice bearing VCaP cells orthotopically implanted into the prostate glands received Terbinafine at 50 mg/kg by intraperitoneal injection every 48 h. Terbinafine reduced tumour growth compared with vehicle controls, with significant differences reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumour-volume determination was carried out with high-resolution 3D ultrasonography.tumour volume 626 mm3 ± 85 mm3[3]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
every 48 h; six weeks of treatment
Vehicle
25μL diluted DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Terbinafine 50 mg/kg25 µL of diluted DMSO i.p. every 48 h, n = 8reduced tumour growth, with significant differences observed after six weeks of treatment (average 1304 mm3 ± 142 mm3 in vehicle controls vs. 626 mm3 ± 85 mm3 in terbinafine-treated cohort, p < 0.01)[3]
Terbinafine 50 mg/kg
Model: male CB17-SCID mice; VCaP cells are orthotopically implanted into the prostate glands; n = 7
Methods and source locations

Compound reported in the paper: Terbinafine

The paper names Terbinafine without stating the salt or form; not verified as the hydrochloride form supplied as A10912. No dose conversion or lot validation.

Results > SQLE inhibition suppresses tumour growth in an orthotopic PCa mouse model (S96, S97, S100); Methods > Orthotopic implantation of PCa cells (S283, S284); Fig. 7 legend (S397)

Tumour-volume determination was carried out with high-resolution 3D ultrasonography.: Tumour-volume determination was carried out with high-resolution 3D ultrasonography.; comparator: 25 µL of diluted DMSO i.p. every 48 h, n = 8 — Results > SQLE inhibition suppresses tumour growth in an orthotopic PCa mouse model (S100); Fig. 7 legend (S397)

Terbinafine 50 mg/kg · Results > SQLE inhibition suppresses tumour growth in an orthotopic PCa mouse model (S97, S100); Methods > Orthotopic implantation of PCa cells (S284)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 78628-80-5
Formula C21H26ClN
Molecular Weight 327.9
Synonyms Zabel; Lamisil
SMILES
CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 58 mg/mL (176.88 mM)
Water Insoluble
Ethanol 58 mg/mL (176.88 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Terbinafine hydrochloride Research References

  1. [1] Li C, Wang Y, Liu D, et al. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut (2022). PMID: 35232776 DOI: 10.1136/gutjnl-2021-325851 Source material
  2. [2] Qiao S, Zou H, Weng Y, et al. Targeting SQLE-mediated cholesterol metabolism to enhance CD8+ T cell activation and immunotherapy efficacy in hepatocellular carcinoma. J Immunother Cancer (2025). PMID: 41005980 DOI: 10.1136/jitc-2025-012345 Source material
  3. [3] Kalogirou C, Linxweiler J, Schmucker P, et al. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun (2021). PMID: 34417456 DOI: 10.1038/s41467-021-25325-9 Source material

Added to your cart

View Cart Checkout
Loading...